[Cyclosporine and psoriasis].

J M Mazer

Home/Archive/PubMed

PubMed · 1784921

[Cyclosporine and psoriasis].

J M Mazer

View original source ↗Export metadata ↓

Abstract

Cyclosporin has proved efficacious in severe and resistant psoriasis. When moderate doses are administered (below 5 mg/kg/day) satisfactory clinical results are obtained at the cost of side-effects that can be controlled, since they are dose-dependent and regress when dosage is reduced. The most important of these side-effects are arterial hypertension and nephrotoxicity due to vasoconstriction of glomerular arteries. It is therefore essential to use low doses (3 mg/kg/day initially) and to measure blood pressure and creatinine levels regularly. This being known, there is no doubt that cyclosporin constitutes a step forward in the treatment of severe psoriasis.

Explore related subjects

Cyclosporine Drug Administration Schedule Humans Psoriasis English Abstract Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

J M Mazer. 1991-10-15. [Cyclosporine and psoriasis].. https://pubmed.ncbi.nlm.nih.gov/1784921/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome.

We report a case of idiopathic inflammatory myopathy accompanied with the presence of anti-Jo1 antibodies and complicated by diffuse parenchymal lung disease (antisynthetase syndrome). Efficacy of different therapeutic agents, including corticosteroids, cyclophosphamide and cyclosporin A, is described. We present beneficial effect of cyclosporin A and corticosteroids regimen, and confirm no benefits of plasmapheresis. An interesting association of the disease onset with toxoplasmosis infection is discussed and difficulties regarding diagnosis of cardiac involvement are addressed. We also review other case reports of this rare disorder of poor prognosis.

Cyclosporine↗

PubMed2007

Update on gingival overgrowth by cyclosporine A in renal transplants.

Severe gingival overgrowth is one of the most frequent side effects in renal transplant patients associated with assumption of cyclosporine A. Several associations with age, sex, dosage, duration of therapy or interval since transplantation have been hypothesized. The introduction of alternative immunosuppressant drugs have been suggested to permit better long-term transplant outcomes and a decrease in incidence of gingival overgrowth. The aim of the present paper is to summarize current knowledge regarding aetiology, pathogenesis and management of gingival overgrowth induced by Cyclosporine A.

Cyclosporine↗

PubMed2007

Severe psoriasis treated with a new macrolide: everolimus.

Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus (Certican; Novartis, Basel, Switzerland) is a new rapamycin-derived macrolide that is used in the prophylaxis of rejection in heart and kidney transplant patients. The mechanism underlying its immunosuppressant and antiproliferative activity is different from, but complementary to, that of calcineurin inhibitors such as ciclosporin. We describe a woman with severe psoriasis treated with everolimus combined with subtherapeutic doses of ciclosporin.

Cyclosporine↗